Bonesupport Holding

Share Issue/Capital Change • Mar 31, 2022

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes.

As per March 31, 2022, the total number of shares in BONESUPPORT Holding AB (publ) amounts to 65,502,522, divided into 64,499,656 ordinary shares with one vote per share and 1,002,866 series C-shares with one-tenth of a vote per share, corresponding to a total of 64,599,942.6 votes.

The change in number of shares and votes is partly due to the exercise of warrants within the employee stock options program 2012/2022. The exercise of warrants increased the number of ordinary shares with 12,000 shares, corresponding to the same number of votes.

The change in number of shares and votes is also due to the conversion of 287,134 series Cshares, which previously have been issued and repurchased within the context of the company's incentive programs LTI 2018 and Board LTI 2018, into ordinary shares during the month of March. The number of ordinary shares has thus increased by 287,134 and the number of series C-shares has decreased by as many shares. Following the conversion, the number of votes has increased by 258,420.6.

For more information contact:

BONESUPPORT AB Emil Billbäck, CEO +46 (0) 46 286 53 70

Håkan Johansson, CFO +46 (0) 46 286 53 70 ir@bonesupport.com

Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 charlotte.stjerngren@cordcom.se www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-03-31 12:00 CEST.

Press Release 31 March 2022 12:00:00 CEST

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport. com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

Change in number of shares and votes in BONESUPPORT Holding AB (publ)